Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics is viewed favorably because its clinical pipeline is maturing, with tovecimig already showing a meaningful efficacy signal in 2L BTC, including 17% ORR versus 5% and median PFS of 4.7 months versus 2.6 months, alongside a 0.44 hazard ratio. Its broader platform remains compelling, as CTX-8371 is enrolling across multiple tumor types, CTX-10726 has begun dosing, and CTX-471 has initiated Phase 2, providing multiple shots on goal from the same antibody-engineering engine. Financially, the company’s roughly $180 million cash balance and runway into 2028 reduce near-term financing risk, supporting continued development while regulatory dialogue on an additional survival trial is resolved.

Compass Therapeutics is facing a weakened fundamental outlook because its lead asset, tovecimig, now carries significant regulatory uncertainty after the FDA recommended an additional survival-benefit trial before BLA submission in previously treated BTC. Although COMPANION-002 showed a statistically significant ORR of 18.0% versus 5.3% and a strong PFS benefit of 4.7 versus 2.6 months (HR 0.44), the ITT OS result was flat at 8.9 versus 9.4 months and heavily confounded by 54% crossover, leaving the approval pathway unclear. As a result, the company has removed tovecimig revenue from its model, and with no confirmatory study currently enrolling, the pipeline is now dependent on later-stage data from CTX-8371 and CTX-10726 to offset the setback.